Press release
Hologic Leads U.S. Adoption as Breast Cancer Diagnostics Market Rises from USD 5,878.0 million in 2025 to USD 12,451.97 million by 2036 at 6.9% CAGR
Note: Source figures show minor rounding variations (USD 5,878.0 million / USD 5,878 million for 2025; USD 6,389.4 million / USD 6,389.41 million for 2026; USD 12,452.0 million / USD 12,451.97 million for 2036).
Get detailed market forecasts, competitive benchmarking, and pricing trends: https://www.factmr.com/connectus/sample?flag=S&rep_id=55
Key Findings
Invasive ductal carcinoma (IDC) is anticipated to account for 40.0% share of the cancer sub-type segment in 2026.
Stage 2 is expected to remain the leading disease stage segment with around 31.0% share in 2026.
Growth is driven by increasing breast cancer incidence numbers and regulatory and clinical guideline mandates converting discretionary testing decisions into standard-of-care protocols.
India and Germany are identified as priority growth markets.
Growth Drivers
FACT.MR analysis identifies three structural forces shaping the market through 2036:
Regulatory and clinical guideline-driven adoption requirements in the EU, USA, and Japan converting previously discretionary testing into standard-of-care protocols.
Technology and platform transitions from analogue and single-marker platforms to digital, multi-analyte, and AI-assisted systems, expanding per-unit revenue and creating replacement cycles.
Geographic demand redistribution toward high-growth emerging markets, with healthcare infrastructure investment and reimbursement system formalisation in India and Germany expanding the accessible buyer base.
Additional demand factors include rising clinical and consumer expectations for diagnostic accuracy and verified safety credentials, shifting purchasing toward premium-positioned products.
Between 2021 and 2025 the market displayed consistent development linked to rising incidence (281,550 new U.S. cases identified in 2021 alone), healthcare budgets, and adoption of AI/ML tools and liquid biopsy technology. Stakeholders including Hologic, Roche, Siemens Healthineers, and GE Healthcare launched novel imaging solutions.
Segment Analysis by Cancer Sub-type
Invasive Ductal Carcinoma: 40.0% of market revenue in 2026. Represents approximately 70-80% of all breast cancer diagnoses. Comprehensive biomarker profiling (oestrogen receptor, progesterone receptor, HER2, and Ki-67) is standard of care.
Multi-gene panel adoption: Genomic Health's Oncotype DX and NanoString's Prosigna expanded per-patient spend via Medicare and European national health system reimbursement for node-negative IDC.
HER2-low classification: DESTINY-Breast04 trial results (2022) established HER2-low as clinically actionable, requiring precise HER2 IHC 1+/2+ quantification.
Liquid biopsy: Foundation Medicine's FoundationOne Liquid CDx received expanded FDA clearance for breast cancer recurrence monitoring in 2024.
Other sub-types analysed: HER2-positive breast cancer, ductal carcinoma in situ (DCIS), invasive lobular carcinoma (ILC), and triple-negative breast cancer (TNBC).
Segment Analysis by Disease Stage
Stage 2: 31.0% of diagnostic revenue in 2026. Aligns with the most comprehensive biomarker testing requirements and multi-gene prognostic panel use.
Oncotype DX chemotherapy decision support validated by TAILORx trial; CMS coverage determination added.
Neoadjuvant response assessment multiplies testing episodes in Stage 2-3 disease.
AI-assisted pathology: Roche's NaviSite digital pathology AI platform and Agilent's Digital Pathology Solutions disclosed 2024 clinical validation data for HER2 and Ki-67 scoring.
Stages covered: Stage 0 (DCIS), Stage 1, Stage 2, Stage 3, Stage 4.
Segment Analysis by Application
Applications segmented as: Hospital Laboratories & Imaging Centers, Diagnostic Pathology Laboratories, Academic & Research Institutes, and Pharmaceutical & Biotechnology Companies.
Country-Level Growth Comparison
Country
CAGR (2026-2036)
Commercial Condition
India
10.8%
National Cancer Grid molecular diagnostics standardisation and PM-JAY oncology benefit package covering HER2 and hormone receptor testing
Germany
9.9%
AGO S3 guideline updates mandating comprehensive biomarker panel testing and EU IVDR-compliant companion diagnostic certification
France
9.0%
Plan Cancer 2021-2030 molecular profiling investment and INCa-certified cancer centre companion diagnostic testing requirements
UK
8.2%
NHS England genomic medicine service breast cancer whole genome sequencing pathway and NICE-approved companion diagnostic testing mandates
USA
7.5%
FDA companion diagnostic approvals for CDK4/6 inhibitors and expanded CMS reimbursement for multi-gene prognostic panel testing
Source: FACT.MR analysis.
Competitive Landscape
Key players profiled: Hologic Inc., Roche Diagnostics, GE HealthCare, Siemens Healthineers AG, Philips Healthcare, Abbott Laboratories, Becton Dickinson and Company, Thermo Fisher Scientific Inc., Fujifilm Holdings Corporation, and Agilent Technologies Inc.
The landscape is consolidating around suppliers with integrated portfolios, regulatory compliance, established reimbursement status, and clinical evidence depth. Regulatory clearance and reimbursement coverage are transitioning to baseline qualification requirements. Clinical evidence generation via prospective studies and real-world data programmes is becoming a continuous competitive obligation.
Recent Developments
Foundation Medicine's FoundationOne Liquid CDx expanded FDA clearance for breast cancer recurrence monitoring (2024).
Roche NaviSite and Agilent Digital Pathology Solutions disclosed 2024 clinical validation data for AI-assisted HER2 and Ki-67 scoring.
DESTINY-Breast04 trial results (2022) established HER2-low as a clinically actionable subgroup.
Historic collaboration among Hologic, Roche, Siemens Healthineers, and GE Healthcare on novel imaging solutions.
Google Health investments supporting AI deep-learning algorithms in mammography and ultrasound systems.
Restraints
The primary restraint is reimbursement coverage complexity across jurisdictions. Suppliers targeting five or more national markets face distinct health technology assessment and coverage determination processes that impose time and cost burdens smaller participants cannot sustain without dedicated market access infrastructure.
How to Choose: Buyer Decision Guide
Procurement and R&D teams evaluating breast cancer diagnostics solutions should prioritise the following criteria drawn from the report's strategic implications:
Secure regulatory clearance and reimbursement coverage in priority markets at least 18 months before planned commercial launch to qualify for institutional procurement shortlists.
Verify guideline compliance (e.g., AGO S3, NCCN, ESMO, NICE) and payer coverage status, as these are replacing price as primary supplier qualification criteria.
Assess depth of clinical evidence, including prospective studies and real-world data programmes that support coverage decisions and guideline endorsement.
Confirm multi-analyte, digital, or AI-assisted platform capabilities that expand per-unit revenue and support replacement cycles.
Evaluate alignment with national reimbursement frameworks such as PM-JAY (India), CMS multi-gene panels (USA), or EU IVDR companion diagnostic certification.
Prioritise suppliers with demonstrated outcomes data for Tier 1 institutional buyers, as vendors lacking these credentials face progressive exclusion from procurement cycles.
Unlock 360° insights for strategic decision making and investment planning: https://www.factmr.com/report/55/breast-cancer-diagnostics-market
Report Scope
The report covers global and regional market sizing across five cancer sub-type segments and five disease stage categories from 2026 to 2036. It includes segment-level revenue forecasts, country-level growth trajectories for 40-plus nations, and competitive positioning analysis. Quantitative units: USD 6,389.41 million (2026) to USD 12,451.97 million (2036) at 6.9% CAGR. Regions: North America, Latin America, Europe, East Asia, South Asia, Oceania, and Middle East & Africa.
Explore More Related Studies Published by Fact.MR Research
Viral Antigens Market- https://www.factmr.com/report/1305/viral-antigens-market
Vestibular Testing Systems Market- https://www.factmr.com/report/1313/vestibular-testing-market
Canine Separation Anxiety Treatment Market- https://www.factmr.com/report/1490/canine-separation-anxiety-treatment-market
Home Diagnostics Market- https://www.factmr.com/report/1892/home-diagnostics-market
Dental Consumables Market- https://www.factmr.com/report/4420/dental-consumables-market
Flag: The quote attributed to analyst S.N. Jha is sourced directly from published commentary on the report page and requires standard PR media sign-off before official press wire dissemination.
- Contact Us -
11140 Rockville Pike, Suite 400, Rockville,
MD 20852, United States
Tel: +1 (628) 251-1583 | sales@factmr.com
About Fact.MR
Fact.MR is a global market research and consulting firm, trusted by Fortune 500 companies and emerging businesses for reliable insights and strategic intelligence. With a presence across the U.S., UK, India, and Dubai, we deliver data-driven research and tailored consulting solutions across 30+ industries and 1,000+ markets. Backed by deep expertise and advanced analytics, Fact.MR helps organizations uncover opportunities, reduce risks, and make informed decisions for sustainable growth.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hologic Leads U.S. Adoption as Breast Cancer Diagnostics Market Rises from USD 5,878.0 million in 2025 to USD 12,451.97 million by 2036 at 6.9% CAGR here
News-ID: 4594323 • Views: …
More Releases from Fact.MR
HBM for Defense and Space Computing Market is Projected to increase from USD 1.8 …
The global HBM for Defense and Space Computing Market reached USD 1.5 billion in 2025 and is projected to increase from USD 1.8 billion in 2026 to USD 9.0 billion by 2036, registering a compound annual growth rate (CAGR) of 17.4% from 2026 to 2036, according to Fact.MR.
Get Detailed Market Forecasts, Competitive Benchmarking, and Pricing Trends: https://www.factmr.com/connectus/sample?flag=S&rep_id=16012
The growing use of artificial intelligence and high-performance computing in defense and space…
HBM CoWoS Packaging Capacity and Supply Demand Market Will Hit USD 32.6 billion …
The global HBM CoWoS Packaging Capacity and Supply Demand Market reached USD 6.4 billion in 2025 and is projected to increase from USD 7.4 billion in 2026 to USD 32.6 billion by 2036, registering a compound annual growth rate (CAGR) of 16.0% from 2026 to 2036, according to Fact.MR.
Get Detailed Market Forecasts, Competitive Benchmarking, and Pricing Trends: https://www.factmr.com/connectus/sample?flag=S&rep_id=16008
The rapid expansion of artificial intelligence workloads is increasing demand for high-performance computing…
Agentic Artificial Intelligence Applications in Vector Database Market is Valued …
The global Agentic Artificial Intelligence Applications in Vector Database Market reached USD 2.3 billion in 2025 and is projected to increase from USD 2.8 billion in 2026 to USD 18.7 billion by 2036, registering a compound annual growth rate (CAGR) of 20.9% from 2026 to 2036, according to Fact.MR.
Get Detailed Market Forecasts, Competitive Benchmarking, and Pricing Trends: https://www.factmr.com/connectus/sample?flag=S&rep_id=16000
Agentic AI applications increasingly require systems capable of storing, retrieving, and interpreting high-dimensional…
AI Training Data Licensing & Royalty Brokerage Services Market Forecasted 31.1% …
The global AI Training Data Licensing and Royalty Brokerage Services Market surpassed USD 2.3 billion in 2025 and is projected to increase from USD 3.0 billion in 2026 to USD 45.0 billion by 2036, registering a compound annual growth rate (CAGR) of 31.1% from 2026 to 2036, according to Fact.MR. The transition from web scraping toward paid content access and structured royalty routing is creating significant demand for licensing and…
More Releases for USD
Bone Cement Market Outlook USD 1,871.10M-USD 3,512.31M
How Is the Bone Cement Market Supporting the Rise of Modern Orthopedic Surgery?
The Bone Cement Market plays a critical role in modern orthopedic and spinal procedures, acting as a foundational material for joint replacement, fracture fixation, and vertebral stabilization. Bone cement is widely used to anchor implants, restore bone structure, and improve patient mobility-making it an essential component of musculoskeletal care.
In 2025, the global bone cement market was valued at…
Autologous Cell Therapy Market Outlook USD 9.31B-USD 54.83B
How Is the Autologous Cell Therapy Market Redefining the Future of Precision Medicine?
The Autologous Cell Therapy Market is rapidly emerging as one of the most transformative areas in modern healthcare, offering highly personalized treatment options for complex and chronic diseases. By using a patient's own cells to repair, replace, or regenerate damaged tissues, autologous cell therapy minimizes immune rejection risks while maximizing therapeutic effectiveness.
In 2025, the global autologous cell therapy…
US Ostomy Care and Accessories Market USD 4.03B-USD 6.75B
How Is the United States Ostomy Care and Accessories Market Evolving to Meet the Needs of a Growing Patient Population?
The United States Ostomy Care and Accessories Market plays a critical role in improving the quality of life for millions of patients who undergo life-altering surgical procedures involving the digestive or urinary systems. Ostomy care products are essential medical devices designed to manage bodily waste safely and discreetly following surgeries such…
PACS Market USD 5.59B in 2025, USD 9.73B by 2035
Picture Archiving and Communication System (PACS) Market Expands as Digital Imaging Transforms Global Healthcare
Introduction: PACS at the Core of Modern Medical Imaging
The healthcare industry is undergoing a rapid digital transformation, with medical imaging playing a critical role in diagnosis, treatment planning, and patient monitoring. At the heart of this transformation lies the Picture Archiving and Communication System (PACS)-a technology that enables the storage, retrieval, management, and sharing of medical images…
Global HEOR Market USD 1.70B-USD 6.03B
Health Economics and Outcomes Research (HEOR) Market Accelerates as Value-Based Healthcare Redefines Global Decision-Making
Introduction: The Growing Importance of HEOR in Modern Healthcare
The global healthcare industry is undergoing a profound transformation, shifting from volume-driven care models to value-based healthcare systems that prioritize patient outcomes, cost efficiency, and real-world effectiveness. At the center of this transformation lies Health Economics and Outcomes Research (HEOR)-a discipline that evaluates the economic value, clinical outcomes, and…
Foam Tape Market Outlook 2035: Industry Growth from USD USD 4.89 Billion (2025) …
The Foam Tape Market plays a vital role in modern industrial and manufacturing ecosystems. Foam tapes are pressure-sensitive adhesive products manufactured using materials such as polyurethane, polyethylene, PVC, and acrylic foam. These tapes are widely used for bonding, sealing, insulation, cushioning, vibration damping, and noise reduction across multiple industries. Their ability to replace traditional mechanical fasteners like screws, bolts, and rivets has positioned foam tapes as a preferred solution in…
